Our Vision : To become a leading specialty biopharmaceutical company in reproductive medicine. PregLem has IP rights on "first in class" compounds which are in clinical and pre-clinical development. At PregLem, we value collaborations with academic units innovating in reproductive medicine
Latest News
12.03.2008
PREGLEM SA INITIATES PHASE Ib CLINICAL TRIAL FOR ITS STEROID SULFATASE INHIBITOR PGL2001
> Read all the news


